MedDataX Logo

Rituximab and Bendamustine in Very Elderly Patients or Elderly Medically Non Fit Patients With Aggressive B-cell Lymphoma

NCT ID: NCT01686321

Last Updated: 2018-12-31

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE2

Total Enrollment

68 participants

Study Classification

INTERVENTIONAL

Study Start Date

2012-07-04

Study Completion Date

2018-08-08

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Bendamustine is a well tolerable and very active agent in the treatment of Non Hodgkin's lymphoma. However, in particular in aggressive B-cell lymphoma, only very few, small studies have investigated the role of bendamustine in the treatment algorithm. The aim of the current B-R-ENDA trial is to investigate efficacy and toxicity of the combination treatment of bendamustine and subcutaneous rituximab in old patients or in elderly patients with high comorbidity who do not qualify for a CHOP like treatment. The results of this study will form the basis of a larger, prospective randomized phase III trial.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Bendamustine is a well tolerable and very active agent in the treatment of Non Hodgkin's lymphoma. However, in particular in aggressive B-cell lymphoma, only very few, small studies have investigated the role of bendamustine in the treatment algorithm. The aim of the current B-R-ENDA trial is to investigate efficacy and toxicity of the combination treatment of bendamustine and subcutaneous rituximab in old patients or in elderly patients with high comorbidity who do not qualify for a CHOP like treatment. The results of this study will form the basis of a larger, prospective randomized phase III trial.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Aggressive Lymphoma

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

elderly patients bendamustine

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Bendamustine and subcutaneous Rituximab

single-arm non randomized

Group Type EXPERIMENTAL

Bendamustine and subcutaneous rituximab

Intervention Type DRUG

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bendamustine and subcutaneous rituximab

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histology: Diagnosis of aggressive CD20+, confirmed by an excisional biopsy of a lymph node or by a sufficiently extensive biopsy of an extranodal involvement if there is no lymph node involvement. It will be possible to treat the following entities in this study as defined by the new WHO classification of 2008: B-NHL, Follicular lymphoma grade IIIb,DLBCL, not otherwise specified (NOS),common morphologic variants: centroblastic,immunoblastic,anaplastic,rare morphologic variants.DLBCL subtypes/entities:T cell/histiocyte rich large B-cell lymphoma, primary cutaneous DLBCL, leg type, EBV-positive DLBCL of the elderly, DLBCL associated with chronic inflammation, primary mediastinal (thymic) large B-cell lymphoma, intravascular large B-cell lymphoma,ALK-positive large B-cell lymphoma, Plasmoblastic lymphoma, Primary effusion lymphoma, B-cell lymphoma, unclassifiable, with features inter¬mediate between diffuse large B-cell lymphoma and Burkitt lymphoma, B-cell lymphoma, unclassifiable, with features inter¬mediate between diffuse large B-cell lymphoma and Hodgkin lymphoma
* Stage: Any stages according to Ann Arbor Classification
* Risk group: All risk groups (IPI 1 to 5)
* Life expectancy Life expectancy of at least 6 weeks, when lymphoma is treated
* Age: Age elder than 81 or Age 61 to 80 and CIRS \>6 not qualifying for CHOP-therapy
* Gender: any
* Performance status: Performance status ECOG 0 - 3. The performance status of each patient is to be assessed at the time of registration which might be after the initiation of pre-phase treatment which, as experience has shown, can result in a significant improvement of the patient´s performance status. A definition of the performance status is provided in Appendix 25.6
* Ability to give informed consent
* Written informed consent of the patient
* Contract of participation signed by the study center and sponsor

Exclusion Criteria

* Already initiated lymphoma therapy (except for the prephase treatment until first application of rituximab)
* Serious accompanying disorder or impaired organ function (except when due to lymphoma involvement), in particular: Heart: angina pectoris CCS \>2, cardiac failure NYHA \>3; Lungs: the patient is to be excluded if the resultant pulmonary function test shows FEV1\<50% or a diffusion capacity \<50% of the reference values: Calculated creatinin clearance \< 10 ml/min (Cockcroft-Gault); Liver: total bilirubin \> 3 mg/dl; Uncontrollable diabetes mellitus (because of prephase treatment with prednisone!)
* Platelets \<100 000/mm3, leukocytes \<2500/mm3 (if not due to lymphoma)
* Known hypersensitivity to the medications to be used
* HIV-positivity
* Acute or chronic active hepatitis
* Poor patient compliance
* Simultaneous participation in other treatment studies
* Prior chemo- or radiotherapy, long-term use of corticosteroids or anti-neoplastic drugs for previous disorder
* Other concomitant tumor disease and/or tumor disease in the past 5 years (except basalioma of the skin and carcinoma in situ)
* CNS involvement of lymphoma (intracerebral, meningeal, intraspinal)
* Active serious infections not controlled by oral or intravenous antibiotics or anti-fungal
* Any medical condition which in the opinion of the investigator places the subject at an unacceptably high risk for toxicities.
* Non-conformity to eligibility criteria.
Minimum Eligible Age

60 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Roche Pharma AG

INDUSTRY

Sponsor Role collaborator

Mundipharma Research GmbH & Co KG

INDUSTRY

Sponsor Role collaborator

University of Göttingen

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Lorenz, Trümper, MD

Prof. Dr.

Responsibility Role PRINCIPAL_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lorenz Trümper, Prof

Role: PRINCIPAL_INVESTIGATOR

University medicine Goettingen

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Prof. Trümper

Göttingen, , Germany

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Germany

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

2010-024004-98

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

DSHNHL-2010-1

Identifier Type: -

Identifier Source: org_study_id